Palavras-chave
prematuro
ibuprofeno
administración oral
tratamiento
Como Citar
Resumo
Introducción: La indometacina y el ibuprofeno endovenosos se usan para cerrar el conducto arterioso persistente del prematuro, pero en Colombia son costosos y escasos. El ibuprofeno oral es una alternativa efectiva y accesible, pero hay dudas sobre su seguridad.
Objetivo: Describir el perfil de seguridad del ibuprofeno oral en el cierre del conducto del prematuro.
Materiales y métodos: Cohorte retrospectiva de prematuros con conducto más repercusión hemodinámica tratados con ibuprofeno oral. Entre los desenlaces se encuentra mortalidad, función renal, hemorragia de vías digestivas altas y perforación intestinal.
Resultados: De 237 casos, se incluyeron 185. Hubo 5 % de fallas renales, 2,7 % de hemorragias de vías digestivas altas y 2,2 % de perforaciones intestinales. Falleció el 10,8 %: por sepsis, el 45 %; por inmadurez extrema, el 35 %, y por enterocolitis, el 20 %.
Conclusión: La incidencia de eventos adversos con ibuprofeno oral fue baja. El principal evento adverso fue falla renal (5 %). El ibuprofeno oral parece ser seguro en el cierre del conducto arterioso del prematuro.
Shannon E, Hamrick, Hansmann G, Hamrick SEG. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010 May;125(5):1020-30.
Laughon MM, Simmons MA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr. 2004 Apr;16(2):146-51.
Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2013;(1):CD0003481.
Keady S, Grosso A. Ibuprofen in the management of neonatal patent ductus arteriosus. Intensive Crit Care Nurs. 2005 Feb;21(1):56-8.
Aranda J V, Thomas R. Systematic review: intravenous Ibuprofen in preterm newborns. Semin Perinatol. 2006 Jun;30(3):114-20.
Neumann R, Schulzke SM, Bührer C. Oral Ibuprofen versus intravenous Ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology. 2012 Jan;102(1):9-15.
Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatrics. 2003 Nov;112(5):e354.
Cherif A, Khrouf N, Jabnoun S, Mokrani C, Amara M Ben, Guellouze N, et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics. 2008 Dec;122(6):e1256-61.
Yang EM, Song ES, Choi YY. Comparison of oral Ibuprofen and intravenous indomethacin for the treatment of patent ductus arteriosus in extremely low birth weight infants. J Pediatr (Rio J). 2013;89(1):33-9.
Neumann R et al. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a sys. Neonatology. 2012 Jan;102(1):16-8.
Gouyon J-B, Kibleur Y. Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infants. Clin Ther. Excerpta Medica; 2010 Sep;32(10):1740-8.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.